Literature DB >> 24821568

Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.

Yuji Takemoto1, Teizaburo Asai, Itsuo Ikezoe, Takako Yano, Masahiro Ichikawa, Shogo Miyagawa, Jun Matsumoto.   

Abstract

BACKGROUND: The neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, laninamivir and peramivir are available in Japan. However, the selective use of NAIs for treating outpatients with influenza has not been clearly defined.
METHODS: We assigned 191 patients with influenza to 4 groups, each treated with a different NAI, and then compared how long it took to alleviate fever and other symptoms and to eliminate the virus.
RESULTS: Alleviation of fever occurred significantly sooner with peramivir than with either zanamivir (p = 0.0002) or oseltamivir (p = 0.0059), but was not significantly different from that with laninamivir (p = 0.0457; p < 0.0083). Other symptoms were also alleviated sooner by peramivir than by the other 3 NAIs.
CONCLUSIONS: The ability of each NAI to alleviate influenza symptoms and fever varied. The appropriate use of NAIs requires further study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821568     DOI: 10.1159/000362436

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

1.  Novel Polyanions Inhibiting Replication of Influenza Viruses.

Authors:  Justyna Ciejka; Aleksandra Milewska; Magdalena Wytrwal; Jacek Wojarski; Anna Golda; Marek Ochman; Maria Nowakowska; Krzysztof Szczubialka; Krzysztof Pyrc
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 2.  Safety and efficacy of peramivir for influenza treatment.

Authors:  Atsuko Hata; Ryoko Akashi-Ueda; Kazufumi Takamatsu; Takuro Matsumura
Journal:  Drug Des Devel Ther       Date:  2014-10-24       Impact factor: 4.162

Review 3.  Japanese Surveillance Systems and Treatment for Influenza.

Authors:  Hassan Zaraket; Reiko Saito
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-10

4.  The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients.

Authors:  John Palmer; Hana M Dobrovolny; Catherine A A Beauchemin
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

Review 5.  Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.

Authors:  Jonghoo Lee; Ju Hee Park; Hyeyoung Jwa; Yee Hyung Kim
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

6.  A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment.

Authors:  Jui-Yi Chen; Shih-Kai Wei; Chih-Cheng Lai; Teng-Song Weng; Hsin-Hua Wang
Journal:  Medicina (Kaunas)       Date:  2020-02-05       Impact factor: 2.430

7.  Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.

Authors:  Momoko Mawatari; Reiko Saito; Akinobu Hibino; Hiroki Kondo; Ren Yagami; Takashi Odagiri; Ikumi Tanabe; Yugo Shobugawa
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

8.  Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study.

Authors:  Shigeki Nakamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Yutaka Saisho; Katsunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno
Journal:  Open Forum Infect Dis       Date:  2017-06-19       Impact factor: 3.835

9.  Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients.

Authors:  Jin Seo Lee; Mi Suk Lee; Yoonseon Park; Jacob Lee; Eun-Jeong Joo; Joong Sik Eom
Journal:  Infect Drug Resist       Date:  2020-05-19       Impact factor: 4.003

10.  Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.

Authors:  Motokazu Kato; Yutaka Saisho; Hiroshi Tanaka; Takuma Bando
Journal:  Influenza Other Respir Viruses       Date:  2020-07-17       Impact factor: 4.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.